Exelixis | EXEL - Ebitda


Exelixis reported $255.4M in EBITDA for its fiscal quarter ending in June of 2026.





Ebitda Change Date
Acadia Pharmaceuticals USD -1.62M 21.94M Mar/2026
Agios Pharmaceuticals USD -108.66M 11.65M Mar/2026
Akebia Therapeutics USD 14.03M 17.19M Mar/2025
Amgen USD 3.86B 1.28B Mar/2026
AstraZeneca USD 5.16B 510M Jun/2026
Bayer EUR 2.14B 2.31B Jun/2026
BioMarin Pharmaceutical USD 146.05M 170.22M Mar/2026
Bristol-Myers Squibb USD 4.24B 1.37B Mar/2026
Cytokinetics USD -169.32M 19.48M Mar/2026
Eisai JPY 34.15B 34.48B Jun/2026
Eli Lilly USD 10.29B 1.86B Mar/2026
Exelixis USD 255.4M 2.89M Jun/2026
Genmab DKK 401M 186M Jun/2026
Glaxosmithkline GBP 2.77B 1.98B Mar/2026
Incyte USD 778.57M 410.6M Jun/2026
Ionis Pharmaceuticals USD -64.53M 135.49M Mar/2026
MacroGenics USD -30.2M 52.15M Mar/2026
Merck USD -1.54B 7.84B Mar/2026
Moderna USD -1.26B 468M Mar/2026
Nektar Therapeutics USD -38.9M 7.09M Mar/2026
Neurocrine Biosciences USD 193.3M 25.1M Mar/2026
Novartis USD 6.48B 1.19B Jun/2026
Pfizer USD 6.01B 18M Jun/2026
Puma Biotechnology USD 729K 11.36M Jun/2024
Sanofi EUR 2.72B 2.94B Mar/2026
Takeda JPY 364.46B 214.21B Jun/2026
Ultragenyx Pharmaceutical USD -155M 55.57M Mar/2026
Xencor USD -34.63M 86.74M Jun/2026